Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25 million Series C financing. OneVentures, a venture capital firm headquartered in Sydney, […]
Intralytix, Inc. announced that its food safety product, CampyShield™, has received GRAS (Generally Recognized as Safe) recognition from the Food and Drug Administration (FDA), GRAS No: GRN 000966. CampyShield™ is a non-chemical antimicrobial preparation containing […]
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase 2 clinical trial of VE303, an orally administered investigational live […]
Improved growth of certain organisms (now known to be bacteria) in the absence of oxygen was conclusively demonstrated by Louis Pasteur in the 1860s. Catalytic removal of oxygen from the incubation atmosphere, allowing surface growth […]
Nanyang Technological University, Singapore (NTU Singapore) and L’Oréal Singapore today launched a new joint laboratory hosted by the Singapore Centre for Environmental Life Sciences Engineering (SCELSE), to conduct research on the community of bacteria, fungi, […]
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection (rCDI). The […]
Human clinical trials within the functional foods and nutraceuticals industry tend to follow a consistent flow, even though aspects of the process are relatively flexible. However, failure to plan & manage a clinical study effectively […]
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today announced positive data from its Phase 2 study evaluating EDP1815 versus […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational Synthetic Biotic™ medicines for the treatment of phenylketonuria (PKU). SYNB1618 […]
The University of Texas MD Anderson Cancer Center and SNIPR BIOME announced a strategic collaboration to advance new CRISPR-based microbiome therapeutics to reduce immune-related adverse events (irAE) in patients being treated with combined immune checkpoint inhibitors. […]
Hundreds of companies globally, funded by over USD $5.9 billion in venture capital to date, are now focused on leveraging the close relationship between humans and their resident microbes. And with new scientific publications on […]